SCHEMBL73645

SCHEMBL73645

CC(C)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
TP53 P04637 1/20 0.38
SLC7A5 Q01650 1/20 0.38
PLA2G2A P14555 1/20 0.37
PLA2G5 P39877 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KDM4E B2RXH2 1/20 0.36
FPR2 P25090 1/20 0.36
MMP2 P08253 2/20 0.35
MMP3 P08254 2/20 0.35
MMP13 P45452 2/20 0.35
ADAMTS4 O75173 1/20 0.35
MMP1 P03956 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551696 1.00 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAGAAHPGD
SCHEMBL16750043 1.00 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAGAAHPGD
SCHEMBL30461437 0.81 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2LMNAGAAHPGD
SCHEMBL21844003 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2TP53TDP1
SCHEMBL16750045 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2TP53TDP1
SCHEMBL24253076 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2TP53TDP1
SCHEMBL21844009 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2TP53TDP1
SCHEMBL22697281 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2LMNAGAAHPGD
SCHEMBL14572731 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2TP53TDP1
SCHEMBL19090792 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US claimed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO claimed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP claimed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN claimed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US claimed
WO-2022204327-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2022-09-29 WO claimed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP claimed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN claimed
EP-2413711-A1 DIPEPTIDE AS FEEDSTUFF ADDITIVE Evonik Degussa GmbH (DE) 2012-02-08 EP claimed
WO-2011147881-A2 CYCLIC DIPEPTIDES AS FEEDSTUFF ADDITIVES EVONIK DEGUSSA GMBH (DE) 2011-12-01 WO claimed
WO-2010112365-A1 DIPEPTIDE AS FEEDSTUFF ADDITIVE EVONIK DEGUSSA GMBH (DE) 2010-10-07 WO claimed
EP-1689426-B1 PHARMACEUTICAL FORMULATIONS FOR THE SUSTAINED RELEASE OF INTERFERONS AND THERAPEUTIC APPLICATIONS THEREOF FLAMEL TECH SA (FR) 2009-12-30 EP claimed
EP-1689425-B1 PHARMACEUTICAL FORMULATIONS FOR THE SUSTAINED RELEASE OF ONE OR MORE ACTIVE PRINCIPLES AND THERAPEUTIC APPLICATIONS THEREOF FLAMEL TECHNOLOGIE SA (FR) 2009-12-09 EP claimed
EP-1567578-B1 POLYAMINO ACIDS FUNCTIONALIZED BY AT LEAST ONE (OLIGO)AMINO ACID GROUP AND THERAPEUTIC USES FLAMEL TECH SA (FR) 2008-06-25 EP claimed
US-20070010652-A1 Polyamino acids functionalised with at least one hydrophobic group and applications thereof particularly therapeutic applications STEPHANIE ANGOT, OLIVIER BREYNE, AND YOU-PING CHAN 2007-01-11 US claimed
US-20260028371-A1 HIGH PERFORMANCE AND ENVIRONMENTALLY COMPATIBLE FILMS, FIBERS, AND MEMBRANES WITH BUNDLEMER BUILDING BLOCKS UNIV DELAWARE (US) 2026-01-29 US disclosed
EP-4612124-A1 AZOTOMYCIN PRODRUGS WITH PREFERENTIAL TUMOR DELIVERY The Johns Hopkins University (US) 2025-09-10 EP disclosed
US-4447613-A Pyridyl esters and thiolesters of aminoalkanoic acids ZOECON CORPORATION (US) 1984-05-08 US disclosed
US-4269981-A Certain pyridylmethyl esters of formamido-lower-alkanoates and derivatives thereof ZOECON CORPORATION (US) 1981-05-26 US disclosed
US-4247701-A Certain pesticidal substituted amino lower-alkanoates or lower-alkano-thioates containing pyridyl in the ester portion ZOECON CORPORATION (US) 1981-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028371-A1 HIGH PERFORMANCE AND ENVIRONMENTALLY COMPATIBLE FILMS, FIBERS, AND MEMBRANES WITH BUNDLEMER BUILDING BLOCKS MB, BCAT2, AAAS ALDH1A1 2793/4885SMN1; SMN2 2076/4885LMNA 1386/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB ALDH1A1 4294/4885SMN1; SMN2 4084/4885LMNA 2077/4885
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCB, PRKCI ALDH1A1 4336/4885SMN1; SMN2 4831/4885LMNA 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.